NYSE:AZN - AstraZeneca Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$37.03 -0.30 (-0.80 %)
(As of 07/20/2018 06:59 AM ET)
Previous Close$37.33
Today's Range$36.96 - $37.35
52-Week Range$28.43 - $37.37
Volume2.81 million shs
Average Volume3.66 million shs
Market Capitalization$94.55 billion
P/E Ratio9.90
Dividend Yield3.67%
Beta0.6
AstraZeneca logoAstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:AZN
CUSIPN/A
Phone44-20-3749-5000

Debt

Debt-to-Equity Ratio1.08
Current Ratio0.73
Quick Ratio0.54

Price-To-Earnings

Trailing P/E Ratio9.90
Forward P/E Ratio22.31
P/E Growth2

Sales & Book Value

Annual Sales$22.47 billion
Price / Sales4.18
Cash Flow$3.3122 per share
Price / Cash11.18
Book Value$6.57 per share
Price / Book5.64

Profitability

EPS (Most Recent Fiscal Year)$4.28
Net Income$3.00 billion
Net Margins12.61%
Return on Equity30.73%
Return on Assets7.44%

Miscellaneous

Employees61,100
Outstanding Shares2,532,900,000
Market Cap$94,553.02

AstraZeneca (NYSE:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a semiannual dividend on Monday, February 5th. Shareholders of record on Friday, February 16th will be given a dividend of $0.95 per share on Monday, March 19th. This represents a yield of 5.62%. The ex-dividend date of this dividend is Thursday, February 15th. View AstraZeneca's Dividend History.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

Shares of AstraZeneca split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were distributed to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) released its quarterly earnings results on Friday, May, 18th. The company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.28 by $0.20. The business earned $5.18 billion during the quarter, compared to analyst estimates of $5.24 billion. AstraZeneca had a net margin of 12.61% and a return on equity of 30.73%. The firm's revenue was down 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.99 earnings per share. View AstraZeneca's Earnings History.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for AstraZeneca.

What guidance has AstraZeneca issued on next quarter's earnings?

AstraZeneca issued an update on its FY18 earnings guidance on Friday, May, 18th. The company provided EPS guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.46.

What price target have analysts set for AZN?

17 brokers have issued twelve-month target prices for AstraZeneca's shares. Their forecasts range from $35.00 to $42.00. On average, they anticipate AstraZeneca's stock price to reach $38.2833 in the next year. This suggests a possible upside of 3.4% from the stock's current price. View Analyst Ratings for AstraZeneca.

What is the consensus analysts' recommendation for AstraZeneca?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 6 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting AstraZeneca?

AstraZeneca saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 7,144,897 shares, a decrease of 34.8% from the June 15th total of 10,959,514 shares. Based on an average daily volume of 3,577,564 shares, the short-interest ratio is presently 2.0 days. Approximately 0.3% of the shares of the company are sold short. View AstraZeneca's Current Options Chain.

Who are some of AstraZeneca's key competitors?

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:
  • Mr. Pascal Soriot, Exec. Director & CEO (Age 59)
  • Mr. Marc Dunoyer, Exec. Director & CFO (Age 66)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 47)
  • Mr. Jefrey Pott, Gen. Counsel
  • Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer

Has AstraZeneca been receiving favorable news coverage?

Media headlines about AZN stock have trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. AstraZeneca earned a news sentiment score of 0.13 on Accern's scale. They also gave news stories about the company an impact score of 47.05 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.52%), Hardman Johnston Global Advisors LLC (0.05%), Bank of Montreal Can (0.04%), World Asset Management Inc (0.00%), Essex Investment Management Co. LLC (0.00%) and BLB&B Advisors LLC (0.00%). View Institutional Ownership Trends for AstraZeneca.

Which major investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including World Asset Management Inc, Daniel Devine & Co, Fulton Bank N.A., Fox Run Management L.L.C., Hardman Johnston Global Advisors LLC, Gofen & Glossberg LLC IL, Atria Investments LLC and Raymond James Trust N.A.. View Insider Buying and Selling for AstraZeneca.

Which major investors are buying AstraZeneca stock?

AZN stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Bank of Montreal Can, Essex Investment Management Co. LLC, BLB&B Advisors LLC, FNY Investment Advisers LLC, Catawba Capital Management VA, RDL Financial Inc. and Private Trust Co. NA. View Insider Buying and Selling for AstraZeneca.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $37.03.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $94.55 billion and generates $22.47 billion in revenue each year. The company earns $3.00 billion in net income (profit) each year or $4.28 on an earnings per share basis. AstraZeneca employs 61,100 workers across the globe.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]


MarketBeat Community Rating for AstraZeneca (NYSE AZN)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  546 (Vote Outperform)
Underperform Votes:  913 (Vote Underperform)
Total Votes:  1,459
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.